Where Can You Report Your Adverse Drug Reactions Or Adverse Events Following Immunization

Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization

Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization

This section provides a comprehensive overview of the procedures and tools available to Healthcare Professionals, Market Authorization Holders and the General Public to report adverse events associated with medicinal products and vaccines in Lebanon.

How to report

You can send the case reports using the following tools:

For Healthcare Professionals and the Public

The Lebanese National Pharmacovigilance Program has adapted two user-friendly tools: one for Adverse Drug Reactions (Vigimobile e-Reporting e-Form) and another for reporting Adverse Events Following Immunization (Vigimobile e-Form). Both tools may be accessed by healthcare professionals and the general public.

The VigiMobile e-Form and e-Reporting e-Form:

The VigiMobile e-Form and e-Reporting e-Form are the latest tools launched in January 2025 by the Lebanese National Pharmacovigilance Program. These digital platforms were introduced to enhance the reporting process, with the e-Reporting e-Form designed for Adverse Drug Reactions (ADRs) and the VigiMobile e-Form specifically for Adverse Events Following Immunization (AEFIs).

How to Download on Android Phones

Scan the QR Code by pressing the link
Click the three dots in the top-right corner
Choose Install app
VigiMobile e-Form/e-Reporting e-Form now appears as an app

How to Download on Apple IOS Phones

Scan the QR Code by pressing the link
Click on the share button
Add VigiMobile to the home screen
VigiMobile e-Form/e-Reporting e-Form now appears as an app

How to Download on Windows

Press on the link
Install from the Browser menu
VigiMobile e-Form/e-Reporting e-Form is now installed

Scan QR Codes to Report:

ADRs Following Medication Use	AEFIs Following Vaccine Use

Or use the following link: LNPVP: e-Reporting eForm	Or use the following link: LNPVP: VigiMobile eForm

Direct Contact with the Lebanese National Pharmacovigilance Program:

You may contact the Lebanese National Pharmacovigilance Program through:

Email Address:

pv@moph.gov.lb, pv.moph@gmail.com

Phone number of the Quality Assurance of Pharmaceutical Products Program: 01-830254

For Market Authorization Holders:

Based on the Ministerial Resolution MR #181 issued in 2021, MAHs should adhere to the internationally agreed ICH guidelines and standards and send the reports in XML format as specified in ICH E2B (R2 or R3) guidelines

(https://www.moph.gov.lb/userfiles/files/Quality%26Safety/PharmacovigilanceSystemInLebanon/Karar%20181-2021.pdf).

All XML files should be sent to the following emails: pv@moph.gov.lb, and pv.moph@gmail.com.

As for what to report or report type, you can refer to Module VI:
https://moph.gov.lb/en/Pages/4/44742/pharmacovigilance-system-lebanon#/en/view/70479/lebanese-guideline-on-good-pharmacovigilance-practices-lgvp-

...

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
B01AC17	AGGRASTAT	B	Tirofiban hydrochloride monohydrate - 0.25mg/ml	0.25mg/ml	Injectable concentrated solution	18,280,324 L.L
N02BA01	ASPIRINE	B	Acetylsalicylic acid - 300mg	0.3g	Tablet	80,631 L.L
S01HA02	ANESTOCIL	B	Oxybuprocaine HCl (Benoxinate HCl) - 0.4%	0.4%	Drops solution	442,124 L.L
G04CA02	APO-TAMSULOSIN CR	G	Tamsulosin HCl - 0.4mg	0.4mg	Tablet	607,417 L.L
C05BB02	AETHOXYSKLEROL	B	Polidocanol (Lauromacrogol 400) - 0.5%	0.5%	Injectable solution	1,441,943 L.L
S01AE07	AROX	G	Moxifloxacin (HCl) - 0.5%	0.5%	Drops	423,310 L.L
J01DH02	AROPEM	G	Meropenem (trihydrate) - 0.5g	0.5g	Injectable powder for solution	995,723 L.L
J01DH02	AROPEM	G	Meropenem - 0.5g	0.5g	Injectable powder for solution	995,723 L.L
J01DH02	AROPEM	G	Meropenem - 0.5g	0.5g	Injectable powder for solution	995,723 L.L
J01DH02	AROPEM	G	Meropenem - 0.5g	0.5g	Injectable powder for solution	19,022,727 L.L
L01XX35	ANAGRELIDE BIOGARAN	G	Anagrelide - 0.5mg	0.5mg	Capsule	15,754,068 L.L
N05BA12	ALPRAZOLAM BIOGARAN	G	Alprazolam - 0.5mg	0.5mg	Tablet, scored	169,324 L.L
N05BA12	ALPROX	G	Alprazolam - 0.5mg	0.5mg	Tablet	383,955 L.L
G04CB02	AVODART	B	Dutasteride - 0.5mg	0.5mg	Capsule	2,660,787 L.L
A03BA01	ATROPINE SULFATE RENAUDIN	G	Atropine sulfate - 0.5mg/ml	0.5mg	Injectable solution	385,683 L.L
L04AD02	ADVAGRAF	B	Tacrolimus monohydrate - 0.5mg	0.5mg	Capsule, prolonged release	13,297,758 L.L
J05AF10	APO-ENTECAVIR	G	Entecavir - 0.5mg	0.5mg	Tablet	28,943,287 L.L
J05AF10	AVIRAVIR	G	Entecavir monohydrate - 0.5mg	0.5mg	Tablet, film coated	32,224,230 L.L
S01GX07	ALLERGODIL	B	Azelastine HCl - 0.5mg/ml	0.5mg/ml	Drops solution	709,549 L.L
A03BA01	ATROPINE	G	Atropine sulfate - 0.5mg/ml	0.5mg/ml	Injectable solution	680,315 L.L
R06AX27	AERIUS	B	Desloratadine - 0.5mg/ml	0.5mg/ml	Solution	403,153 L.L
R06AX27	AERIALLERG	G	Desloratadine - 0.5mg/ml	0.5mg/ml	Syrup	200,233 L.L
C05BB02	AETHOXYSKLEROL	B	Polidocanol (Lauromacrogol 400) - 1%	1%	Injectable solution	1,732,213 L.L
D11AX18	ALMIRAL	G	Diclofenac sodium - 1% w/w	1% w/w	Gel	396,434 L.L
L01BC01	ALEXAN	G	Cytarabine - 1,000mg/20ml	1,000mg/20ml	Injectable solution	2,848,946 L.L
J01CR02	AMOXICILLINA/ ACIDO CLAVULANICO	G	Amoxicillin (sodium) - 1g, Clavulanic Acid (potassium) - 200mg	1.2g	Injectable powder for solution	16,577,136 L.L
M02AA	AIRTAL DIFUCREM 1.5%	B	Aceclofenac - 1.5g/100g	1.5%	Cream	536,193 L.L
J01DC02	AXETINE	G	Cefuroxime sodium - 1.5g	1.5g	Injectable powder for solution	2,273,782 L.L
C03BA11	ADEX	G	Indapamide - 1.5mg	1.5mg	Tablet, prolonged release	296,989 L.L
B05BA01	AMINOVEN INFANT	B	L-Leucine - 13g/l, L-Isoleucine - 8g/l, L-Lysine Acetate - 12g/l, L-Methionine - 3.12g/l, L-Phenylalanine - 3.75g/l, L-Threonine - 4.40g/l, L-Tryptophan - 2.01g/l, L-Valine - 9g/l, Arginine - 7.5g/l, L-Histidine - 4.76g/l, Glycine - 4.15g/l, L-Taurine - 0.40g/l, L-Serine - 7.67g/l, L-Alanine - 9.3g/l, L-Proline - 9.71g/l, N-Acetyl-L-Tyrosine - 5.176g/l, N-Acetyl-L-Cysteine - 0.70g/l, L-Malic Acid - 2.62g/l	10%	Injectable solution	880,217 L.L

...